Perspective's promising PRRT trial results and solid financial position make CATX stock an attractive long-term investment ...

Learn about the promising Monopar Therapeutics Inc. MNPR-101 treatment targeting solid tumors and how it aims to reduce ...

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals ...

anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants ...

many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree 2,5-7 Nemluvio ® (nemolizumab) is the first approved monoclonal ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today ...